This technology is an immunotherapy approach that targets the cell surface marker CD58 to enhance antitumor immunity and bypass immune evasion mechanisms, therefore improving treatment outcomes in patients.
Despite the success of immune checkpoint inhibitors in treating cancer, many patients develop resistance, diminishing the overall effectiveness of these therapies. Current treatments often fail to address immune evasion mechanisms and disruptions in critical pathways. Additionally, there is a pressing need for reliable biomarkers to identify which patients are likely to respond to treatment. Overcoming these resistance mechanisms will improve the precision and impact of cancer immunotherapies.
This technology targets CD58 to overcome cancer immunotherapy resistance. By modulating CD58 expression, it directly addresses key resistance mechanisms, such as defects in the IFNγ-JAK/STAT pathway, impaired antigen presentation, and immune evasion. Additionally, this approach identifies important gene signatures related to immune fitness therefore offering biomarkers for optimizing patient selection and therapy customization. By directly targeting CD58, this technology enhances the efficacy of immunotherapies and enables the development of combination treatments to overcome therapeutic resistance. This technology has been validated in patient-derived melanoma co-cultures and autologous tumor-infiltrating lymphocyte co-cultures.
Patent Pending(US20240294643)
IR CU21046, CU21047
Licensing Contact: Joan Martinez
